10:56 AM EST, 01/07/2025 (MT Newswires) -- Immix Biopharma ( IMMX ) said Tuesday six patients dosed in a phase 1b safety run-in segment of a trial of its experimental NXC-201 treatment of relapsed or refractory AL Amyloidosis successfully completed the trial's safety evaluation.

The safety run-in segment dosed three patients at 150 million CAR-T cells and three patients at 450 million CAR-T cells.

Immix said enrollment can now advance across US study sites at a dose of 450 million CAR-T cells.

AL Amyloidosis is a life-threatening disorder of plasma cells in the bone marrow.

Price: 2.29, Change: -0.01, Percent Change: -0.43